February 26, 2026

AHA Issues Pediatric Hypertriglyceridemia Statement

The scientific statement defines pancreatitis and atherosclerotic cardiovascular disease risk thresholds and outlines causes and management in youths.

Conexiant

February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 19, 2026

Income, BMI Linked to Colon Capsule Completion

Danish screening data identify clinical and socioeconomic factors that significantly influence whether colon capsule exams are completed.

Conexiant

February 19, 2026

GLP-1 RAs Linked to Higher Hair Loss Risk

A large matched cohort study quantifies the association between glucagon-like peptide-1 receptor agonist use and nonscarring alopecia

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 18, 2026

Weight Regain Rapidly Follows GLP-1 Cessation

Systematic review finds most lost weight returns within two years of stopping weight management medication

Conexiant

February 17, 2026

Exercise Matters Following Cancer

Postdiagnosis physical activity was associated with lower cancer mortality across several cancer types.

Conexiant

February 16, 2026

Intermittent Fasting Shows No Edge Over Standard Diets

Cochrane review finds the approach produces similar weight loss and quality-of-life outcomes compared with conventional calorie restriction

Conexiant

February 12, 2026

Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

Conexiant